Literature DB >> 9445316

The systemic fibrinolytic activity of intrapleural streptokinase.

C W Davies1, S Lok, R J Davies.   

Abstract

Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445316     DOI: 10.1164/ajrccm.157.1.97-03094

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  BTS guidelines for the management of pleural infection in children.

Authors:  I M Balfour-Lynn; E Abrahamson; G Cohen; J Hartley; S King; D Parikh; D Spencer; A H Thomson; D Urquhart
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

Review 3.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 4.  Pleural effusion.

Authors:  A R Medford; A Medford; N Maskell
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

Review 5.  Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas.

Authors:  S A Sahn
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

6.  Severe haemorrhage following intrapleural streptokinase therapy for haemothorax after myocardial revascularisation with the left internal mammary artery.

Authors:  J B Winter; J G Zijlstra; T S van der Werf
Journal:  Neth Heart J       Date:  2002-10       Impact factor: 2.380

7.  Randomised trial of intrapleural urokinase in the treatment of childhood empyema.

Authors:  A H Thomson; J Hull; M R Kumar; C Wallis; I M Balfour Lynn
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

8.  Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam.

Authors:  Abdo N Farret; Eduardo P Azevedo; Fernanda N Raffin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

9.  The Epidemiology of Traumatic Hemothorax in a Level I Trauma Center: Case for Early Video-assisted Thoracoscopic Surgery.

Authors:  Jana B MacLeod; Jeffrey S Ustin; Joseph T Kim; Fran Lewis; Grace S Rozycki; David V Feliciano
Journal:  Eur J Trauma Emerg Surg       Date:  2009-12-22       Impact factor: 3.693

10.  Massive hemothorax following administration of intrapleural streptokinase.

Authors:  Feng Yih Chai; Yeh Chunn Kuan
Journal:  Ann Thorac Med       Date:  2011-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.